Summary
This prediction ended on 01.11.18 with a price of €13.53. The price of Merus BV has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -16.67%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Merus BV | - | - | - | - |
| iShares Core DAX® | 1.085% | -0.846% | 12.464% | 58.472% |
| iShares Nasdaq 100 | -1.665% | -3.306% | 1.502% | 84.473% |
| iShares Nikkei 225® | 3.863% | 6.308% | 22.272% | 56.185% |
| iShares S&P 500 | 0.111% | -1.337% | 1.101% | 58.320% |
Comments by stratec for this prediction
In the thread Merus BV diskutieren
Merus will yield meaningful clinical data in the near future.
A lucrative partnership was signed with Incyte last year for which they received $120 million upfront and a common share purchase of $80 million. Incyte in return received exclusive rights for up to 11 bispecific antibody research programs utilizing Merus' Biclonics technology, which included two preclinical immuno-oncology candidates.
The technology of Merus has the potential to be sufficiently differentiated from monoclonal antibodies due to improved tumor cell killing activity and lower toxicity.
(Laufzeit überschritten)